ABSTRACT
Grade IV glioma, formerly known as glioblastoma multiforme (GBM) is the most aggressive and lethal type of brain tumor, and its treatment remains challenging in part due to extensive interpatient heterogeneity in disease driving mechanisms and lack of prognostic and predictive biomarkers. Using mechanistic inference of node-edge relationship (MINER), we have analyzed multiomics profiles from 516 patients and constructed an atlas of causal and mechanistic drivers of interpatient heterogeneity in GBM (gbmMINER). The atlas has delineated how 30 driver mutations act in a combinatorial scheme to causally influence a network of regulators (306 transcription factors and 73 miRNAs) of 179 transcriptional “programs”, influencing disease progression in patients across 23 disease states. Through extensive testing on independent patient cohorts, we share evidence that a machine learning model trained on activity profiles of programs within gbmMINER significantly augments risk stratification, identifying patients who are super-responders to standard of care and those that would benefit from 2nd line treatments. In addition to providing mechanistic hypotheses regarding disease prognosis, the activity of programs containing targets of 2nd line treatments accurately predicted efficacy of 28 drugs in killing glioma stem-like cells from 43 patients. Our findings demonstrate that interpatient heterogeneity manifests from differential activities of transcriptional programs, providing actionable strategies for mechanistically characterizing GBM from a systems perspective and developing better prognostic and predictive biomarkers for personalized medicine.
Competing Interest Statement
NB is a founder and owns equity (founder shares) and ST owns equity in Sygnomics, which is a privately owned biotechnology company focusing on commercializing the Systems Genetic Network Analysis (SYGNAL) technology for personalized medicine applications. AP is a consultant for and has equity interest in Sygnomics.
Funding Statement
S.T. is supported by R01-CA259469, Washington Research Foundation Grant No: GA-00117 and Andy Hill Cancer Research Endowment (CARE) Fund. W.W., K.K. and C.M. are supported by R01-CA259469. M.M. is supported by R01-CA259469 and Washington Research Foundation Grant No: GA-00117. Y.H. is supported by R01-CA259469 and Andy Hill Cancer Research Endowment (CARE) Fund. A.N. is supported by NSF-2150265. A.P.P. is supported by R01-NS119650, the Burroughs Wellcome Career Award for Medical Scientists, and Discovery Grant from the Kuni Foundation. P.H. and H.L. were funded by the Ben and Catherine Ivy Foundation and are currently supported by R01-CA259469 and philanthropic funding from the Swedish Medical Center Foundation. C.C. is supported by R01-CA259469. J.P. was funded by a fellowship from the NIH (F32-CA247445) and currently supported by NIH grant R01-CA259469. N.S.B. is supported by R01-CA259469, Washington Research Foundation Grant No: GA-00117 and Andy Hill Cancer Research Endowment (CARE) Fund.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The ethics committee/IRB/Compliance office of Institute for Systems Biology, Seattle, WA, USA gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors